TEL AVIV, Israel, February 4, 2013 /PRNewswire/ --
InspireMD, Inc. ("InspireMD" or the "Company") (OTC: NSPRD) announced financial results for the period ended Dec. 31, 2012, the second quarter of its 2013 fiscal year.
Revenue for the period was up 165% over the Sept. 30, 2012 quarter, reflecting early results of marketing initiatives that were launched following the announcement of positive results of the MASTER trial of the Company's MGuard™ Embolic Protection Stent (EPS™) at the 24th Annual Transcathter Cardiovascular Therapeutics (TCT) scientific meeting in Miami on October 24, 2012.
Alan Milinazzo , newly appointed President and CEO of InspireMD said, "The interventional cardiology community was clearly enthusiastic about the MASTER trial's results. The study's positive results set the stage for enhanced sales and marketing activities which began during the first week of December at the important ICI meeting in Tel Aviv."
The MASTER trial's positive results, presented at the TCT by Study Chairman Gregg W. Stone , MD, reported that the novel MGuard EPS provided a statistically and clinically significant advantage in acute treatment of heart attack patients, indicating lower incidences of post stenting adverse events compared to the control group, and the potential to prolong survival.
MGuard EPS is CE Mark approved. It is not approved for sale in the U.S. by the Food and Drug Administration (FDA) at this time. The Company has filed an Investigational Device Exemption with the U.S. FDA to initiate a Premarket Approval trial.
Key Financial Highlights 2Q Ended Dec. 31, 2012 Include:
- Revenue for the quarter ended Dec. 31, 2012 totaled $1.4 million, which was slightly above the $1.3 million recorded in the same period in 2011, but 165% higher than th
|SOURCE InspireMD, Inc.|
Copyright©2012 PR Newswire.
All rights reserved